About alpha tau medical ltd - DRTS
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
DRTS At a Glance
Alpha Tau Medical Ltd.
Kiryat HaMada Street 5
Jerusalem, Jerusalem 9777605
| Phone | 972-3-577-4115 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -42,627,000.00 | |
| Sector | Health Technology | Employees | 112 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DRTS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.65 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.177 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.041 |
DRTS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -380,598.214 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DRTS Liquidity
| Current Ratio | 7.452 |
| Quick Ratio | 7.452 |
| Cash Ratio | 7.319 |
DRTS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -44.223 |
| Return on Equity | -60.998 |
| Return on Total Capital | -46.933 |
| Return on Invested Capital | -52.021 |
DRTS Capital Structure
| Total Debt to Total Equity | 17.803 |
| Total Debt to Total Capital | 15.113 |
| Total Debt to Total Assets | 12.879 |
| Long-Term Debt to Equity | 16.336 |
| Long-Term Debt to Total Capital | 13.867 |